Neuronetics, Inc. (STIM) Borrowing debt
- Total debt · latest quarter (USD): Value (m); Formula and calculation Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted). Period ending 2026-06-30..
- Net cash · latest quarter: Value (m); Formula and calculation Cash and cash equivalents plus current marketable securities less interest-bearing debt; negative net cash is displayed as net debt. Period ending 2026-06-30..
- Debt / assets · latest quarter: Value (m); Formula and calculation Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted) / total assets. Period ending 2026-06-30..
Borrowing debt
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Total debt · latest quarter (USD) | (m) | Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted). Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Net cash · latest quarter | (m) | Cash and cash equivalents plus current marketable securities less interest-bearing debt; negative net cash is displayed as net debt. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Debt / assets · latest quarter | (m) | Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted) / total assets. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Borrowing debt due within one year | (m) | Long-term Debt, Current Maturities |
| Borrowing debt due after one year | 61.52M USD | Long-term Debt, Excluding Current Maturities |
| Commercial paper | (m) | |
| Cash and current securities | (m) | Cash and Cash Equivalents, at Carrying Value |
| Borrowing debt | (m) | Long-term Debt, Current Maturities · Long-term Debt, Excluding Current Maturities |
| Total assets | 131.53M USD | Assets |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Total debt | Net cash / debt | Borrowing debt due within one year (USD) | Borrowing debt due after one year (USD) | Commercial paper (USD) | Cash and current securities (USD) | Total assets (USD) | Debt / assets |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | (m) | (m) | $61.52M | (m) | (m) | $131.53M | (m) |
| 2026-03-31 | (m) | (m) | (m) | $61.30M | (m) | (m) | $125.44M | (m) |
| 2025-12-31 | (m) | (m) | (m) | $65.81M | (m) | (m) | $141.55M | (m) |
| 2025-09-30 | (m) | (m) | (m) | $65.67M | (m) | (m) | $145.47M | (m) |
| 2025-06-30 | (m) | (m) | (m) | $55.54M | (m) | (m) | $134.65M | (m) |
| 2025-03-31 | (m) | (m) | (m) | $55.34M | (m) | (m) | $141.99M | (m) |
| 2024-12-31 | (m) | (m) | (m) | $55.15M | (m) | (m) | $140.90M | (m) |
| 2024-09-30 | (m) | (m) | (m) | $46.00M | (m) | (m) | $74.12M | (m) |
| 2024-06-30 | (m) | (m) | $13.61M | $46.15M | (m) | (m) | $96.81M | (m) |
| 2024-03-31 | (m) | (m) | (m) | $59.44M | (m) | (m) | $103.81M | (m) |
| 2023-12-31 | (m) | (m) | (m) | $59.28M | (m) | (m) | $115.83M | (m) |
| 2023-09-30 | (m) | (m) | (m) | $36.85M | (m) | (m) | $92.99M | (m) |
| 2023-06-30 | (m) | (m) | (m) | $36.71M | (m) | (m) | $100.39M | (m) |
| 2023-03-31 | (m) | (m) | (m) | $36.64M | (m) | (m) | $103.60M | (m) |
| 2022-12-31 | (m) | (m) | $13.13M | $22.83M | (m) | (m) | $116.88M | (m) |
| 2022-09-30 | (m) | (m) | $8.75M | $27.01M | (m) | (m) | $119.23M | (m) |
| 2022-06-30 | (m) | (m) | $4.38M | $31.21M | (m) | (m) | $122.95M | (m) |
| 2022-03-31 | (m) | (m) | (m) | $35.44M | (m) | (m) | $129.94M | (m) |
| 2021-12-31 | (m) | (m) | (m) | $35.34M | (m) | (m) | $141.22M | (m) |
| 2021-09-30 | (m) | (m) | $35.10M | (m) | (m) | (m) | $143.07M | (m) |
| 2021-06-30 | (m) | (m) | (m) | $34.94M | (m) | (m) | $148.10M | (m) |
| 2021-03-31 | (m) | (m) | (m) | $34.79M | (m) | (m) | $152.31M | (m) |
| 2020-12-31 | (m) | (m) | (m) | $34.62M | (m) | (m) | $78.66M | (m) |
| 2020-09-30 | (m) | (m) | $34.54M | (m) | (m) | (m) | $78.34M | (m) |
| 2020-06-30 | (m) | (m) | $34.37M | (m) | (m) | (m) | $79.99M | (m) |
| 2020-03-31 | (m) | (m) | (m) | $34.21M | (m) | (m) | $88.45M | (m) |
| 2019-12-31 | (m) | (m) | $11.25M | $19.90M | (m) | (m) | $100.17M | (m) |
| 2019-09-30 | (m) | (m) | $7.50M | $23.45M | (m) | (m) | $105.48M | (m) |
| 2019-06-30 | (m) | (m) | $3.75M | $27.01M | (m) | (m) | $109.43M | (m) |
| 2019-03-31 | (m) | (m) | (m) | $30.57M | (m) | (m) | $113.44M | (m) |
| 2018-12-31 | (m) | (m) | (m) | $30.39M | (m) | (m) | $117.02M | (m) |
| 2018-09-30 | (m) | (m) | $5.00M | $25.20M | (m) | (m) | $118.98M | (m) |
| 2018-06-30 | (m) | (m) | $2.50M | $27.50M | (m) | (m) | $28.34M | (m) |
| 2017-12-31 | (m) | (m) | (m) | $29.56M | (m) | (m) | $38.94M | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Profound Medical Corp. (PROF) | $0.206B | -7.37 | |
| PRO DEX INC (PDEX) | United States | $0.234B | 13.64 |
| UTAH MEDICAL PRODUCTS INC (UTMD) | United States | $0.238B | 20.93 |
| InfuSystem Holdings, Inc (INFU) | United States | $0.253B | 22.52 |
| Lucid Diagnostics Inc. (LUCD) | United States | $0.170B | |
| Anika Therapeutics, Inc. (ANIK) | United States | $0.272B | -51.71 |
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |
| Cytosorbents Corp (CTSO) | United States | $0.274B | -1.29 |
| KORU Medical Systems, Inc. (KRMD) | United States | $0.151B | -106.78 |
| TriSalus Life Sciences, Inc. (TLSI) | United States | $0.283B | -9.92 |